Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells $1,660,584.33 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 15,161 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the completion of the sale, the director now owns 152,396 shares of the company’s stock, valued at $16,691,933.88. The trade was a 9.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Blueprint Medicines Trading Down 0.6 %

Shares of BPMC stock opened at $114.91 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The company has a market cap of $7.30 billion, a price-to-earnings ratio of -54.46 and a beta of 0.61. Blueprint Medicines Co. has a 1 year low of $72.24 and a 1 year high of $121.90. The firm has a fifty day moving average price of $95.80 and a 200-day moving average price of $95.33.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. The business had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business’s quarterly revenue was up 126.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($2.20) earnings per share. As a group, equities analysts predict that Blueprint Medicines Co. will post -3.67 earnings per share for the current year.

Hedge Funds Weigh In On Blueprint Medicines

Several large investors have recently added to or reduced their stakes in the company. Quarry LP bought a new stake in shares of Blueprint Medicines during the 3rd quarter valued at $32,000. R Squared Ltd purchased a new position in shares of Blueprint Medicines in the fourth quarter valued at about $51,000. Covestor Ltd grew its position in shares of Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 403 shares in the last quarter. Quantbot Technologies LP bought a new stake in Blueprint Medicines during the 3rd quarter valued at approximately $108,000. Finally, Values First Advisors Inc. purchased a new position in Blueprint Medicines in the 3rd quarter worth approximately $122,000.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BPMC. Wells Fargo & Company cut their price target on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. HC Wainwright reiterated a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a report on Friday, November 15th. Needham & Company LLC restated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Monday, January 13th. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Finally, StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $122.72.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.